Trial Profile

A monotherapy dose-escalation study of RMC-8839

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RMC-8839 (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors REVOLUTION Medicines

Most Recent Events

17 May 2022 New trial record
09 May 2022 According to a Revolution Medicines media release, the company expects to announce dosing of the first patient in a monotherapy dose- escalation study of RMC-8839 in late 2023 or early 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com